150 related articles for article (PubMed ID: 14594937)
1. Comparable outcomes of radiation therapy without high-dose methotrexate for patients with primary central nervous system lymphoma.
Ishikawa H; Hasegawa M; Tamaki Y; Hayakawa K; Akimoto T; Sakurai H; Mitsuhashi N; Niibe H; Tamura M; Nakano T
Jpn J Clin Oncol; 2003 Sep; 33(9):443-9. PubMed ID: 14594937
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
3. Analysis of radiotherapy in 1054 patients with primary central nervous system lymphoma treated from 1985 to 2009.
Shibamoto Y; Sumi M; Takemoto M; Tsuchida E; Onodera S; Matsushita H; Sugie C; Tamaki Y; Onishi H
Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):653-60. PubMed ID: 25034088
[TBL] [Abstract][Full Text] [Related]
4. Whole brain radiotherapy improves survival outcomes in primary CNS lymphoma patients ineligible for systemic therapy.
Song J; Samant R; Jay M; Chaudry H; Fan XY; MacDonald D; Bence-Bruckler I; Nair V
Support Care Cancer; 2020 Nov; 28(11):5363-5369. PubMed ID: 32140974
[TBL] [Abstract][Full Text] [Related]
5. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
[TBL] [Abstract][Full Text] [Related]
6. Evolution of the treatment of primary central nervous system lymphoma in a Regional Cancer Center of South India: Impact of high-dose methotrexate on treatment outcome.
Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu G; Lokesh KN; Rajeev LK
J Cancer Res Ther; 2020; 16(1):13-17. PubMed ID: 32362603
[TBL] [Abstract][Full Text] [Related]
7. Primary central nervous system lymphoma: age and performance status are more important than treatment modality.
Corry J; Smith JG; Wirth A; Quong G; Liew KH
Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):615-20. PubMed ID: 9635710
[TBL] [Abstract][Full Text] [Related]
8. Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy.
Park JS; Lim DH; Ahn YC; Park W; Kim SJ; Kim WS; Kim K
Jpn J Clin Oncol; 2017 Nov; 47(11):995-1001. PubMed ID: 28973509
[TBL] [Abstract][Full Text] [Related]
9. Improved survival with combined chemo-radiotherapy in primary central nervous system lymphoma.
Abdelsalam M; El-Husseiny G; Akhtar S; Khafaga Y; Al-Shabana M; AlHusaini H; El Weshi A; Rahal M; Maghfoor I
Hematol Oncol Stem Cell Ther; 2010; 3(3):128-34. PubMed ID: 20890070
[TBL] [Abstract][Full Text] [Related]
10. Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s.
Shibamoto Y; Ogino H; Hasegawa M; Suzuki K; Nishio M; Fujii T; Kato E; Ishihara S; Sougawa M; Kenjo M; Kawamura T; Hayabuchi N
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):809-13. PubMed ID: 15936564
[TBL] [Abstract][Full Text] [Related]
11. Role of radiation therapy in primary central nervous system lymphoma : KROG 14-20 Collaborative Study of Brain and Lymphoma Committee.
Koh HK; Kim IH; Kim TM; Lim DH; Oh D; Cho JH; Kim WC; Kim JH; Chung WK; Jeong BK; Kang KM; Hong S; Suh CO; Kim IA
J Neurooncol; 2017 Dec; 135(3):629-638. PubMed ID: 28939931
[TBL] [Abstract][Full Text] [Related]
12. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
Bessell EM; Graus F; Lopez-Guillermo A; Lewis SA; Villa S; Verger E; Petit J
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):501-8. PubMed ID: 15145169
[TBL] [Abstract][Full Text] [Related]
13. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL).
Nelson DF
J Neurooncol; 1999 Jul; 43(3):241-7. PubMed ID: 10563430
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center experience.
Ney DE; Reiner AS; Panageas KS; Brown HS; DeAngelis LM; Abrey LE
Cancer; 2010 Oct; 116(19):4605-12. PubMed ID: 20572045
[TBL] [Abstract][Full Text] [Related]
16. Primary central nervous system lymphoma. Results at the University of California at Los Angeles and review of the literature.
Selch MT; Shimizu KT; De Salles AF; Sutton C; Parker RG
Am J Clin Oncol; 1994 Aug; 17(4):286-93. PubMed ID: 8048389
[TBL] [Abstract][Full Text] [Related]
17. Role of 23.4 Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy.
Kim N; Lim DH; Yoon SE; Kim SJ; Kim WS
J Neurooncol; 2021 Sep; 154(2):207-217. PubMed ID: 34331673
[TBL] [Abstract][Full Text] [Related]
18. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments.
Bessell EM; López-Guillermo A; Villá S; Verger E; Nomdedeu B; Petit J; Byrne P; Montserrat E; Graus F
J Clin Oncol; 2002 Jan; 20(1):231-6. PubMed ID: 11773174
[TBL] [Abstract][Full Text] [Related]
19. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
[TBL] [Abstract][Full Text] [Related]
20. Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen.
Yamanaka R; Shinbo Y; Sano M; Homma J; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Morii K; Onda K; Tanaka R
Leuk Lymphoma; 2007 Jun; 48(6):1119-26. PubMed ID: 17577775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
